Kornimate/medical-research-clean huggingface dataset:
influenza vaccination in patients living with hiv in the northern region

Conditions: HIV

Summary: anyone living with the human immunodeficiency virus (hiv) has an indication for annual influenza vaccination. (vaccination schedule and vaccination recommendations 2019). influenza is a viral infection that has a significant impact on the health care system. however, vaccination coverage in france is still insufficient with regard to the objectives set at 75% by the who and the european commission. for the 2019-2020 seasonal influenza vaccination campaign, flu vaccination by volunteer pharmacists has become possible throughout the country. studies that have estimated vaccination coverage among hiv-positive populations are rare and show very low rates.

cross-sectional study via a self-questionnaire given to all hiv-infected patients coming for a scheduled consultation as part of their hiv follow-up in the spring of 2020. non-opposition letter given to the patient. collection of data a posteriori from the medical file recorded in the enadis patient file.

Eligibility criteria:
inclusion criteria: * any adult person living with hiv presenting for a follow-up consultation in the spring of 2020 * people who do not read french may participate if they wish with the help of a medical or paramedical staff member. * patient did not object exclusion criteria: * minor patients * major under guardianship, curatorship, protected person
corneal thinning during topical bevacizumab therapy

Conditions: Corneal Neovascularization

Summary: the purpose of this study is to determine whether topical bevacizumab is safe or not when used in corneal neovascularization for long term period.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of corneal neovascularization * must be able to apply eyedrop exclusion criteria: * have active keratitis
post-prandial glucose and insulin levels in type 2 diabetes mellitus patients after consumption of ready-to-eat mixed meals

Conditions: Diabetes Mellitus, Type 2

Summary: the aim of the current study was to compare the effects of three ready-to-eat mixed meals, with a high fiber content and low glycemic index, on postprandial glycemic and insulinemic response in patients with type 2 diabetes mellitus (t2dm).

the current study followed a prospective, three-way, cross-over design. twenty four patients with t2dm consumed three ready-to-eat mixed meals, i.e. "wild greens pie" (meal 1), "chicken burgers with boiled vegetables" (meal 2) and "vegetable moussaka" (meal 3) and an oral glucose load, all providing 50g of carbohydrates. venous blood was collected at 0, 30, 60, 90 and 120 minutes postprandial for serum glucose and insulin measurements. the test meals were consumed by study participants between 8:30 to 9:00 am and within 10-15 minutes under a researcher's supervision, following collection of the fasting blood sample. no parallel fluid intake was allowed. the portion size in the case of each one of the three test meals was adjusted to contain 50g of carbohydrates. however, the three test meals were considerably differentiating among them with respect to their content in calories and the remaining macronutrients.

Eligibility criteria:
inclusion criteria: * subjects are eligible if they are 45-75 years of age * non-insulin-dependent t2dm with an elapsed time since diagnosis of more than 3 years * body mass index (bmi) value higher than 20 kg/m2 * hba1c levels of 6.5 to 11% exclusion criteria: * insulin-dependent t2dm * cardiovascular (i.e. coronary heart disease, stroke etc.) * liver and/or renal disease

Keywords: glycemic response diabetes insulinemic response mixed meals glycemic index
management of temporomandibular disorders (tmd)

Conditions: Temporomandibular Disorder

Summary: temporomandibular disorders (tmd) are a group of pathologies of the temporomandibular joint, their muscles, and related structures. it is considered a musculoskeletal disorder of the masticatory system, and it has a 25% prevalence in overall population. in 3% - 7% of the population, pain and dysfunction leads to the need for treatment . the etiology of tmd is multifactorial .

temporomandibular disorder is characterized by signs and symptoms that include pain, muscle tenderness, joint noises, and a limited range of motion. the normal distance of mouth opening (inter-incisal distance) is 53 - 58mm. a minimal limit of 40 mm might be used to identify patients with limited aperture, whereas 35 mm is the necessary criteria for diagnosing disc displacement without reduction after unforced maximal aperture . due to all symptoms involved, a multidisciplinary approach is recommended for effective management of such cases. conservative management of tmd treatment includes occlusal splints; physical therapy; oral medication (nsaids and muscle relaxants); and orthodontic treatment. physical therapy is an important option used to reduce pain and inflammation and to improve oral mobility and function. phonophoresis is a method which intensifies the delivery of a topical agent into underlying tissues by ultrasound . it has been used with topical application of steroids, salicylate, anesthetic agents, methly nicotinate, nsaid . it is one of the many modalities for the treatment of musculoskeletal disorders. corticosteroids are used to reduce inflammation in systemic disease, local tendanitis, myositis, and other soft tissues. while these drugs are most often taken orally, they have also been applied transcutaneously by rubbing, injection, electrical current, or ultrasound. transcutaneous drug delivery has a faster distribution rate into the system once it diffuses through the outer layer of the skin, quickly reaching the arterioles in the epithelium it is carried out systemically. as the blood moves through the vessels, part of the drug leaks into the surrounding tissues. these advantages have justified researching different methods to enhance transcutaneous delivery, avoiding unnecessary prolonged drug contact.

Eligibility criteria:
inclusion criteria: * patients 20- 50 years showing tmd * pain \> 3 on visual analog scale (vas) * failed pharmacological treatment exclusion criteria: * electrical stimulator or pacemaker * cancer or any other severe or mental diseases * osteoarthritis, inflammation, infection, or radiation on the tmj articulation, * joint cement or plastic components on tmj articulation
canadian study of trandolapril on blood pressure in hypertensive patients

Conditions: Hypertension

Summary: the in-mau-tion study is conducted to determine the percentage of hypertensive participants with or without diabetes reaching chep (canadian hypertension education program) defined blood pressure targets. additionally, the study assesses change in renal function (microalbuminuria, estimated glomerular filtration rate) in hypertensive participants treated with trandolapril (mavik®) and examines patient satisfaction with trandolapril (mavik®) therapy.

there are no interventional implications in this study. the study runs under consideration of canadian hypertension education program guidelines and as per standard practice of care. data collection is recorded on the appropriate case report forms. the data collected consist of: patient demographics (gender, race, age, weight), blood pressure readings, heart rate, coexisting comorbidities, concomitant chronic medications (generic name and dosage), indication and dose for trandolapril (mavik®) and patient compliance. laboratory values (microalbuminuria, estimated glomerular filtration rate) are only collected if the data are available for each patient. for baseline values (study day 0), any laboratory value recorded within the past year prior to the baseline visit (visit 1) is recorded, if the value is available. as per canadian hypertension education program recommendations and as a support and educational measure, patients are provided with (1) educational tools (nutrition guidebooks) and (2) home blood pressure monitoring devices. as per research and development guidelines, blood pressure devices were retrieved at the end of the study. approximately 8,000 hypertensive participants were enrolled in the study at up to 700 sites across canada. sample size estimations were based on the assumption that 67.2% of non-diabetic hypertensive participants (assumed to make up to 69% of the eligible participant population) would reach a blood pressure target of \<140/90mm hg, while 22% of diabetes participants (31% of the eligible population) would meet a blood pressure target of \<130/80 mm hg with trandolapril (mavik®) therapy.

Eligibility criteria:
inclusion criteria: * adults capable of providing consent and who have uncontrolled hypertension * participants were either treatment-naïve or had uncontrolled hypertension on their existing antihypertensive medication. exclusion criteria: * participants were excluded from participation in the study if they had been taking trandolapril (mavik®), alone or in combination, for more than 1 month prior to enrollment.

Keywords: uncontrolled hypertension trandolapril
sibyl: observation of therapy response with liquid biopsy evaluation

Conditions: Non-small Cell Lung Cancer; Colorectal Cancer; Breast Cancer

Summary: the purpose of sibyl is to generate clinical validity data for the ability of a future version of guardant360 developed by guardant health to measure response to systemic therapy in patients with unresectable advanced solid tumors. it is necessary to collect clinical data points and treatment outcomes in order to demonstrate clinical validity for longitudinal monitoring with ctdna and correlation of ctdna dynamics with therapeutic response, as evaluated by standard methods, including recist 1.1 and ct scan measurements.


Eligibility criteria:
* will be treated with a first- or second-line systemic and/or oral standard of care regimen at the enrolling site * patient is either treatment naive and has not yet commenced first line soc therapy or patient has completed a prior line of soc therapy and will commence subsequent line of soc therapy * provide written informed consent to participate in the study * diagnosed with an unresectable advanced solid malignancy and have a histologically confirmed cancer that qualifies for inclusion, defined as: * non-small cell lung cancer (stage iii-iv) * colorectal adenocarcinoma (stage iii-iv) * breast cancer (stage iii-iv) exclusion criteria: * history of a prior solid or hematological malignancy within 5 years of enrollment * life expectancy \< 12 weeks * unable to collect baseline blood sample prior to starting soc regimen * is participating in an interventional clinical trial or another observational study that is evaluating the performance of another genomic test for detecting/predicting clinical response/progression
a trial of cm-at in children with autism with all levels of fct (the blum study)

Conditions: Autism

Summary: the purpose of this study is to determine whether cm-at is safe and effective in treating the core symptoms of autism in children with all levels of fecal chymotrypsin.

autism is clearly a significant cause of disability in the pediatric population. many children with autism exhibit impaired protein digestion which may or may not manifest in self-restricted diets. the inability to digest protein affects the availability of essential amino acids in the body. cm-at is designed to enhance protein digestion thereby potentially restoring the pool of essential amino acids. essential amino acids play a critical role in the expression of several genes important to neurological function and serve as precursors to key neurotransmitters such as serotonin and dopamine. cm-at is a proprietary enzyme that is designed as a granulated powder taken three times daily.

Eligibility criteria:
inclusion criteria: * meets the current diagnostic and statistical manual with mental disorders (dsm-iv-tr) for autism (autistic disorder), screened by scq and confirmed by adi-r; exclusion criteria: * patient weighing \< 13kg (28.6 lbs) * previous allergy to porcine (pork) products * previous history of severe head trauma or stroke, loss of consciousness, seizure (or need for seizure medication either present or past) within one year of entering study or uncontrolled systemic disease * diagnosis of: hiv, cerebral palsy, endocrine disorder, pancreatic disease, muscular dystrophy, known genetic disorder, blood dyscrasia, ongoing gi disease * evidence of severe, moderate or uncontrolled systemic disease; and/or any co-morbid condition which in the investigator's or medical director's opinion makes it undesirable for the subject to participate in the study or jeopardizes compliance with the protocol; * within 30 days of starting the study, certain supplementation, chelation or dietary restriction (a 30 day washout period would be required for inclusion); * ongoing dietary restriction for allergy or other reasons except nut allergies (lactose-free allowable); * use of of any stimulant medication must be discontinued 5 days prior to entering the study. * subject must have a stable dose of ssri's for at least 30 days. * inability to ingest study drug and/or follow prescribed dosing schedule

Keywords: autism
the effect of addition of metformin to sglt2 in diabetic patients with heart failure with preserved ejection fraction

Conditions: Heart Failure With Preserved Ejection Fraction; Diabete Type 2

Summary: a prospective open-label, randomized controlled study to evaluate the efficacy of the addition of metformin to sglt2 in diabetic patient with preserved ejection fraction

regardless of the benefits noted with sglt2is, metformin is recommended as first-line therapy for glycemic control in individuals with t2dm and hf, including hfpef, with estimated glomerular filtration rates (egfrs) ≥30 ml/min/1.73 m2. this is based on the demonstrated experience with long-term use; its safety, low cost, and low side effect profile; as well as observational (not clinical trial) data suggesting a 20% relative risk reduction in mortality in individuals with hf, including hfpef. nevertheless, it is worth mentioning that metformin is a common anti-diabetic drug with both systemic and cardioprotective benefits in addition to its hypoglycaemic effect. at the cellular level metformin activates adenosine monophosphate-activated protein kinase (ampk) an important regulator of several metabolic pathways resulting in enhanced glucose utilisation, reduction of protein synthesis and improvement of mitochondrial function. furthermore, metformin has been shown to reduce collagen accumulation and potentially reduce lv hypertrophy and improve diastolic function in the diabetic myocardium. the cardio protection afforded by metformin treatment seems to result from interference with tgf-beta signaling pathway and activation of the amp-kinase signaling cascade. a recent systematic review and meta regression analysis have shown that metformin treatment was associated with a reduction in mortality in patients with hfpef. in addition, treatment with metformin of non-diabetic metabolic syndrome patients with diastolic dysfunction, on top of lifestyle counseling, was associated with improved diastolic function. nevertheless, a recent met analysis showed that initial sglt2 inhibitor/metformin combination therapy has glycaemic and weight benefits compared with either agent alone and appears relatively safe. high dose sglt2 inhibitor/metformin combination therapy appears to have modest weight, but no glycaemic benefits compared with the low dose combination therapy. based on that we our aim is to evaluate the efficacy of the addition of metformin to sglt2 in diabetic patient with preserved ejection fraction

Eligibility criteria:
inclusion criteria: age of 40 years to 74 years. hfpef (≥ 50%) written informed consent of the subject to participate in the study. new york heart association functional class i-iv. diabetic patients sgl-2 naive. newly diagnosed heart failure of preserved ejection fraction exclusion criteria: patients with heart failure with reduced ejection fraction (\ 9 known allergy to metformin end- stage liver disease cancer pregnancy or lactation

Keywords: metformin sglti hfpef
micropulse laser trabeculoplasty as adjunctive treatment in patients with pseudoexfoliation glaucoma

Conditions: Pseudoexfoliation Glaucoma; Primary Open-angle Glaucoma

Summary: this study aims to evaluate the effect of a single session of micropulse laser trabeculoplasty (mlt) on cornea in eyes with primary open glaucoma (poag) and pseudoexfoliation glaucoma (pexg).

patients with pexg under prostaglandine analogue monotherapy with inadequate iop control are treated with 360-degrees 532nm mlt. patients are evaluated at 1 day, 1 month, 3 months, 6 months and 12 months post-mlt. after trabeculoplasty patients are maintained in treatment with the same drug regimen as pre-mlt.

Eligibility criteria:
inclusion criteria: * patients with poag or pexg under treatment with glaucoma agents requiring additional reduction of iop, age older than 18 years, patients willing to provide informed consent to participate in the study and to adhere to the follow-up schedule. exclusion criteria: * pre-existing corneal pathology or scar, history of any previous ocular surgery or any planned ocular surgery during the study, history of prior laser trabeculoplasty, end-stage glaucoma with advanced visual field defect, monocular patients, history of trauma, and concurrent systemic or topical steroid use * patients unable to present for follow up

Keywords: pseudoexfoliation glaucoma primary open-angle glaucoma micropulse laser trabeculoplasty intraocular pressure
effects of drainage in laparoscopic cholecystectomy

Conditions: Acute Cholecystitis; Empyema of Gallbladder; Abscess of Gallbladder

Summary: during laparoscopic surgery for an acutely inflamed gallbladder, most surgeons routinely insert a drain. however, no consensus has been reached regarding the need for drainage in these cases, and the use of a drain remains controversial. this study is coordinated to find out the surgical outcomes and perioperative morbidity according to the insertion of drain after laparoscopic cholecystectomy. investigators expect that the routine use of a drain after laparoscopic cholecystectomy for an acutely inflamed gallbladder will have no effects on the postoperative morbidity.

drain has been widely used in many abdominal surgeries for therapeutic purposes such as the removal of infected debris or abscess, and supporting the healing of leakage or fistula. although the usability of therapeutic drain is commonly accepted, the efficacy of prophylactic drain still has been debated. most surgeons have inserted prophylactic drain with expectations that the drain would be helpful for early detection of postoperative bleeding or leakage, and also prevention of intra-abdominal abscess through removing debris or curd. however, there are only few evidence-based studies for the actual effectiveness of prophylactic drain and the objections against the routine use of drain have been raised. most surgeons have placed the drain after cholecystectomy with expectations that it could help to detect postoperative bleeding or bile leakage and prevent intra-abdominal infection. however, there is a lack of evidence regarding the role of drain in laparoscopic cholecystectomy for acutely inflamed gallbladder and surgeons have placed the drain based on their experiences and beliefs, not on evidence-based guidelines. in the previous retrospective study, \[4\] we described that the routine drain use in laparoscopic cholecystectomy for acutely inflamed gallbladder has no advantage to detect bile leak or bleeding and it was no helpful to prevent the postoperative morbidities such as intra-abdominal abscess or wound infection. the aim of present multicenter trial is to assess the value of routine drain use in laparoscopic cholecystectomy for acutely inflamed gallbladder in a large, randomized controlled prospective study.

Eligibility criteria:
inclusion criteria: * acutely inflamed gallbladder exclusion criteria: * chronic cholecystitis * gallbladder polyp or gallbladder cancer * the patient who underwent reduced port surgery * the patient who underwent common bile duct exploration during the operation * the patient who underwent concurrent operation * the patient who had past history of upper abdominal surgery * the patient who had a immunodeficiency state * the case which had a suspicion of delayed bile leakage * the case which had a incomplete cystic duct ligation * the patient who underwent open conversion surgery during the operation * the patient who had a high risk of bleeding
efficacy of myofascial induction as a manual therapy technique in patients with anxiety

Conditions: Anxiety

Summary: this study evaluates the efficacy of a myofascial intervention as a technique within manual therapy in the treatment of clinical anxiety in adults. half of the participants will receive a myofascial intervention program, while the other half will receive a sham myofascial intervention.

within physiotherapy, some studies have been carried out with psychological outcome measures, mainly from therapeutic exercise, but there continues to be an important documentary gap and the few results are not conclusive. the myofascial approach is presented as an effective tool for the treatment of different pathologies, mainly musculoskeletal. however, few are the studies that relate it to psychological variables and specifically to improve anxiety levels. the myofascial approach is proposed as a fast and low-cost tool for the management of clinical anxiety.

Eligibility criteria:
inclusion criteria: * be between 18 and 65 years old * subjects with high levels of anxiety * subjects who speak and understand spanish correctly * subjects without previous experience in myofascial treatment exclusion criteria: * subjects with a clinical history of cognitive impairment * subjects with systemic, neurological or muscular diseases * subjects with some type of aneurysm diagnosed * subjects with diagnosed extremely high blood pressure * subjects with diagnosed malignant tumors * subjects with diagnosed vertebrobasilar insufficiency * subjects with a diagnosed dermatological condition * subjects diagnosed with epilepsy * pregnant women or with the possibility that they may be

Keywords: anxiety myofascial induction myofascial release manual therapy physiotherapy